Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients.

Hałoń A, Nowak-Markwitz E, Donizy P, Matkowski R, Maciejczyk A, Gansukh T, Györffy B, Spaczyński M, Zabel M, Lage H, Surowiak P.

J Histochem Cytochem. 2012 Jul;60(7):491-501. doi: 10.1369/0022155412446978. Epub 2012 Apr 17.

PMID:
22511598
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.

Torng PL, Mao TL, Chan WY, Huang SC, Lin CT.

Gynecol Oncol. 2004 Feb;92(2):559-67.

PMID:
14766248
[PubMed - indexed for MEDLINE]
3.
4.

High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R.

Clin Exp Metastasis. 1999;17(10):799-808.

PMID:
11089877
[PubMed - indexed for MEDLINE]
5.

[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].

Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.

Ai Zheng. 2004 Oct;23(10):1194-8. Chinese.

PMID:
15473934
[PubMed - indexed for MEDLINE]
6.

MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.

Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G, Reich R.

Gynecol Oncol. 1999 Jun;73(3):372-82.

PMID:
10366463
[PubMed - indexed for MEDLINE]
7.

Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.

Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Daraï E.

Oncol Rep. 2012 Apr;27(4):1049-57. doi: 10.3892/or.2011.1608. Epub 2011 Dec 22.

PMID:
22200690
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.

Ara T, Fukuzawa M, Kusafuka T, Komoto Y, Oue T, Inoue M, Okada A.

J Pediatr Surg. 1998 Aug;33(8):1272-8.

PMID:
9722003
[PubMed - indexed for MEDLINE]
9.

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.

Suzuki M, Iizasa T, Fujisawa T, Baba M, Yamaguchi Y, Kimura H, Suzuki H.

Invasion Metastasis. 1998-1999;18(3):134-41.

PMID:
10474026
[PubMed - indexed for MEDLINE]
10.

Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.

Schwandner O, Schlamp A, Broll R, Bruch HP.

Int J Colorectal Dis. 2007 Feb;22(2):127-36. Epub 2006 Aug 2.

PMID:
16896992
[PubMed - indexed for MEDLINE]
11.

Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM.

Eur J Cancer. 2001 Nov;37(16):2040-9.

PMID:
11597382
[PubMed - indexed for MEDLINE]
12.

Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.

Gakiopoulou H, Nakopoulou L, Siatelis A, Mavrommatis I, Panayotopoulou EG, Tsirmpa I, Stravodimos C, Giannopoulos A.

Clin Cancer Res. 2003 Nov 15;9(15):5573-81.

PMID:
14654538
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.

Afzal S, Lalani el-N, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M, Stamp GW.

Lab Invest. 1996 Feb;74(2):406-21.

PMID:
8780160
[PubMed - indexed for MEDLINE]
15.

Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.

Sharma R, Chattopadhyay TK, Mathur M, Ralhan R.

Oncology. 2004;67(3-4):300-9.

PMID:
15557792
[PubMed - indexed for MEDLINE]
16.

Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells.

Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R.

Int J Cancer. 2001 Aug 15;93(4):507-15.

PMID:
11477554
[PubMed - indexed for MEDLINE]
17.
18.

The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.

Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T.

Oncology. 2005;68(2-3):196-203. Epub 2005 Jul 4.

PMID:
16006757
[PubMed - indexed for MEDLINE]
19.

Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.

Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, Mavrommatis J, Keramopoulos A.

Mod Pathol. 2002 Jan;15(1):26-34.

PMID:
11796838
[PubMed - indexed for MEDLINE]
Free Article
20.

Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis.

Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y.

Clin Cancer Res. 2004 Jan 15;10(2):634-40.

PMID:
14760086
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk